Application of oncolytic virus or combination of oncolytic virus, arterin and bevacizumab in treatment of liver cancer
The invention relates to the technical field of medicines, provides an application of a novel oncolytic virus VG161 in preparation of a medicine for treating liver cancer, and further provides an application of the novel oncolytic virus VG161, an arterin monoclonal antibody and bevacizumab (A + T) in preparation of a medicine group for treating liver cancer. The invention also provides a pharmaceutical composition for treating liver cancer, the pharmaceutical composition comprises a leading drug and a follow-up drug, the leading drug is composed of the oncolytic virus VG161 and pharmaceutically acceptable auxiliary materials, and the follow-up drug is composed of the arterizumab and the bevacizumab; through in-vitro cell tests, the VG161 single drug can effectively kill liver cancer cells, through in-vivo experiments of mice, the VG161 single drug can effectively treat tumors in a liver cancer mouse model, and after the VG161 is combined with an A + T scheme, the treatment effect is further improved. The method can be widely applied to treatment of middle and advanced liver cancer patients with system treatment failure..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 13. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIANG TINGBO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-13, Last update posted on www.tib.eu: 2023-10-09, Last updated: 2023-10-13 |
|---|
| Patentnummer: |
CN115463163 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016889371 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016889371 | ||
| 003 | DE-627 | ||
| 005 | 20231013134300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016889371 | ||
| 035 | |a (EPA)CN115463163 | ||
| 035 | |a (EPA)84365490 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIANG TINGBO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of oncolytic virus or combination of oncolytic virus, arterin and bevacizumab in treatment of liver cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-13, Last update posted on www.tib.eu: 2023-10-09, Last updated: 2023-10-13 | ||
| 520 | |a The invention relates to the technical field of medicines, provides an application of a novel oncolytic virus VG161 in preparation of a medicine for treating liver cancer, and further provides an application of the novel oncolytic virus VG161, an arterin monoclonal antibody and bevacizumab (A + T) in preparation of a medicine group for treating liver cancer. The invention also provides a pharmaceutical composition for treating liver cancer, the pharmaceutical composition comprises a leading drug and a follow-up drug, the leading drug is composed of the oncolytic virus VG161 and pharmaceutically acceptable auxiliary materials, and the follow-up drug is composed of the arterizumab and the bevacizumab; through in-vitro cell tests, the VG161 single drug can effectively kill liver cancer cells, through in-vivo experiments of mice, the VG161 single drug can effectively treat tumors in a liver cancer mouse model, and after the VG161 is combined with an A + T scheme, the treatment effect is further improved. The method can be widely applied to treatment of middle and advanced liver cancer patients with system treatment failure. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHEN YINAN |4 aut | |
| 700 | 0 | |a SONG WEI |4 aut | |
| 700 | 0 | |a YANG ZIFAN |4 aut | |
| 700 | 0 | |a GUO SIDA |4 aut | |
| 700 | 0 | |a WANG ZIJUN |4 aut | |
| 700 | 0 | |a LIN DANNI |4 aut | |
| 700 | 0 | |a LI YUWEI |4 aut | |
| 700 | 0 | |a LIANG XINGMEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 13. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:13 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84365490/publication/CN115463163A1?q=CN115463163 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 13 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 13 |c 12 | ||